Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 13/20 | 0.74 |
| ▸ | DRD2 | P14416 | 10/20 | 0.74 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4527921 | 0.89 | DRD3 (0.63) | DRD3DRD2DRD4HTR1AHTR2A | |
| SCHEMBL16463565 | 0.86 | DRD2 (1.00) | DRD3DRD2DRD4HTR1AHTR2A | |
| SCHEMBL3730702 | 0.81 | NAMPT (0.56) | DRD3DRD2NAMPTPRMT5WDR77 | |
| SCHEMBL314986 | 0.80 | DRD2 (0.83) | DRD3DRD2DRD4HTR2A | |
| SCHEMBL17117322 | 0.79 | NAMPT (0.82) | NAMPT | |
| SCHEMBL3704595 | 0.77 | NAMPT (0.82) | NAMPT | |
| SCHEMBL17117223 | 0.77 | NAMPT (0.82) | NAMPT | |
| SCHEMBL6081560 | 0.77 | NAMPT (0.72) | NAMPTPRMT5WDR77 | |
| SCHEMBL3721059 | 0.77 | PRMT5 (0.54) | DRD3DRD2HTR2ANAMPTPRMT5 | |
| SCHEMBL5658383 | 0.76 | HTR1A (0.67) | DRD2HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | DRD3 10/4885DRD2 3/4885DRD4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.